GlaxoSmithKline Australia

Pharmaceuticals

This joint venture was formed in 2015 as a result of a three-part transaction between GSK (63.5% stake) and Novartis (36.5%). The complex deal also involved GSK acquiring Novartis' global vaccines business, while Novartis bought GSK's oncology business.

Medicinal and Pharmaceutical Product Manufacturing

One of the top five pharmaceutical companies in the world. Completed a series of asset swaps with Novartis in 2015 worth more than $20bn, which includes forming a consumer health joint venture.

Pharmaceuticals manufacturer

Novartis was created in 1996 through the merger of 2 Swiss companies, Ciba-Geigy and Sandoz. Completed a complex three-part transaction with GSK in 2015: GSK acquired Novartis' global vaccines business, Novartis bought GSK's oncology business, and the two companies formed a Consumer Healthcare joint venture. Novartis now operates in just four areas - novel drugs, its Alcon eye care products, its Sandoz generic drugs business, and the GSK joint venture.